NDAINHALATIONAEROSOL, METERED
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
VANCERIL DOUBLE STRENGTH (beclomethasone dipropionate) by Merck & Co. is anti-inflammatory activity. Approved for asthma, allergic rhinitis. First approved in 1996.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANCERIL DOUBLE STRENGTH (beclomethasone dipropionate) is an inhaled corticosteroid approved for asthma and allergic rhinitis that works by inhibiting inflammatory cells and mediators to reduce airway inflammation. The prodrug is rapidly converted to its active form (17-BMP), which exhibits approximately 13 times the glucocorticoid receptor binding affinity of dexamethasone. It delivers topical anti-inflammatory activity with a favorable ratio of efficacy to systemic corticosteroid effects at recommended doses.
LOE Approaching
Product is entering loss of exclusivity phase; commercial teams should expect market contraction and consolidation of support resources.
Mechanism of Action
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and…
Indications (2)
Worked on VANCERIL DOUBLE STRENGTH at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.